Dementia with Lewy Bodies Consortium

2021 Global Lewy Body Dementia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Pharmaceutical, Health, Mental health, Lewy body dementia, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Psychiatry, Learning disabilities, Abnormal psychology, Aging-associated diseases, Dementia, Lewy body, Lewy, Dementia with Lewy Bodies Consortium

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Lewy Body Dementia patients, history of the disease at the population level (Lewy Body Dementia prevalence, Lewy Body Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nLewy Body Dementia patient flow: Lewy Body Dementia prevalence, diagnosed, and drug-treated patients\nDemographics: Lewy Body Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Lewy Body Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Lewy Body Dementia patients segments through age groups, gender, and disease sub-types\nEvaluate Lewy Body Dementia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005374/en/\n'

Groundbreaking research award established to discover an accurate method of diagnosing Lewy body dementia

Retrieved on: 
Thursday, April 15, 2021
Cognitive disorders, Lewy body dementia, Psychiatric diagnosis, Branches of biology, Psychiatry, Dementia, Aging-associated diseases, Clinical medicine, Lewy body, Lewy, Dementia with Lewy bodies, Dementia with Lewy Bodies Consortium

Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.

Key Points: 
  • Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.
  • The hope is that this will lead to an accurate method of diagnosing the disease giving patients and their loved ones clarity about the prognosis.
  • "Shared pathology across Parkinson\'s disease and Lewy body dementia means that better understanding the biology of one can help advance research into the other, growing the impact of this program across diagnostic lines.
  • To learn more about the award and to see how you can help support this initiative, visit americanbrainfoundation.org/cocm\n'

Lewy Body Dementia Treatment Market Size Worth $5.31 Billion By 2027 | Polaris Market Research

Retrieved on: 
Tuesday, December 22, 2020
Cognitive disorders, Branches of biology, Psychiatric diagnosis, Psychiatry, Abnormal psychology, Aging-associated diseases, Learning disabilities, Lewy body dementias, Dementia, Lewy, Dementia with Lewy Bodies Consortium, Hvonruden13/Lewy body dementia

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- The global lewy body dementia treatment market is projected to reach USD 5.31 billion by 2027according to a new study conducted by Polaris Market Research the market is anticipated to register a CAGR of 5.1% from 2020 to 2027.

Key Points: 
  • NEW YORK, Dec. 22, 2020 /PRNewswire/ -- The global lewy body dementia treatment market is projected to reach USD 5.31 billion by 2027according to a new study conducted by Polaris Market Research the market is anticipated to register a CAGR of 5.1% from 2020 to 2027.
  • An increased government effort to spread awareness regarding the treatment for lewy body dementia and the rising prevalence of brain-related disorders is foreseen to strengthen the market growth.
  • North America is forecasted to take the major lead in the global market for lewy body dementia treatment.
  • Feel Free To Ask Our Industry Experts At : https://www.polarismarketresearch.com/industry-analysis/lewy-body-dement...
    Polaris Market Research has segmented the Lewy Body Dementia Treatment market report on the basis of drug type, indication, distribution channel, and region
    Lewy Body Dementia Treatment Market By Drug Type (Revenue USD Million, 2016 2027)

The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”

Retrieved on: 
Wednesday, October 14, 2020
Mental health, Research, Entertainment, Biotechnology, Film & Motion Pictures, Health, Pharmaceutical, General Health, Science, Cognitive disorders, Abnormal psychology, Entertainers, Comedians, Lewy Body Dementia Association, Lewy body dementia, LBD, Lewy body, Lewy, Dementia, Robin Williams, Dementia with Lewy Bodies Consortium, Lewy Body Dementia Association, Acadia Pharmaceuticals

The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the new film Robins Wish, a documentary detailing the late actor Robin Williams courageous battle with the neurodegenerative disorder, Lewy body dementia (LBD).

Key Points: 
  • The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the new film Robins Wish, a documentary detailing the late actor Robin Williams courageous battle with the neurodegenerative disorder, Lewy body dementia (LBD).
  • Lewy body dementia is also the most misdiagnosed dementia, and healthcare provider education is needed to enable early recognition, diagnosis and treatment.
  • Robin Williams unknowingly battled LBD and unfortunately, he is not alone.
  • The Lewy Body Dementia Association (LBDA) is the nations leading authority on Lewy body dementias (LBD) and is dedicated to continuous outreach, education, research, and support for those affected with LBD and their families.